Research graph
References from Abrocitinib in elderly patients with moderate-to-severe atopic dermatitis: A real-world study of clinical outcomes and appetite changes. Local targets link to admitted publications; unresolved targets remain external evidence.
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
10.1016/s0140-6736(20)30732-7 · 2020 · External reference
Long-Term safety of abrocitinib in moderate-to-severe atopic dermatitis: integrated analysis by Age
10.1016/j.jaip.2025.02.040 · 2025 · External reference
Abrocitinib for atopic dermatitis: a step forward
10.1016/s0140-6736(20)31284-8 · 2020 · External reference
Efficacy and safety of abrocitinib in elderly Chinese patients with moderate-to-severe atopic dermatitis: a single-center, retrospective study
2026 · External reference
Abrocitinib safety in geriatric patients: the need for a holistic assessment
10.1016/j.jaad.2026.02.126 · 2026 · External reference
